Tom Miller is a scientist and entrepreneur with focus on the nexus of AI, chemistry, and biology. He spent over 10 years as a tenured professor at Caltech, publishing more than 130 peer-reviewed articles and patents and receiving numerous awards for research excellence. Tom is co-founder and CEO of Iambic Therapeutics - previously known as Entos AI - disrupting the therapeutics landscape with a unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated drugs. The Iambic platform has been demonstrated to deliver best-in-class and first-in-class development candidates to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Iambic has recently announced an oversubscribed $100m Series B raise to demonstrate that the company’s lead programs deliver clinical efficacy for patients with urgent unmet need.